Opening a new frontier in the fight against atherosclerosis PlaqueTec is pursuing a better understanding of the biological mechanisms of coronary artery disease (CAD) to advance the development of precision medicine. CAD, where atherosclerotic plaque build-up narrows or blocks the arteries that supply blood to the heart, is a leading cause of death globally. Current treatment approaches are one-size-fits-all and therefore ineffective for many patients. To address this, PlaqueTec has developed a proprietary technology and data analysis platform to endotype patients and uncover potential biomarkers of coronary vascular function and plaque progression. A more detailed understanding of patient endotypes will …

5 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Revolutionizing treatment for leukaemia relapse. Spearheading the development of a novel PNP inhibitor poised to revolutionize treatment for leukaemia patients facing relapse post-stem cell transplantation. Oncology

59 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Creating breakthrough therapies. Changing lives. Antion Biosciences SA (Antion) is a Swiss biopharmaceutical company developing novel gene and gene-modified cell therapies to treat and cure diseases with significant unmet medical needs. Our proprietary technologies allow for the creation of multimodal treatments that aim to substantially enhance clinical safety and efficacy. We have a number of products in preclinical development, and it is our mission to translate our proprietary technologies into meaningful therapies for the benefit of patients. We are fully committed to creating high-value therapeutic assets, while developing strategies to ensure broad accessibility of our treatments, especially to resource poor …

72 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Unlocking the therapeutic potential of AAT AATec Medical GmbH is a biotech company developing a product platform based on recombinant alpha-1 antitrypsin (AAT) for the treatment of inflammatory diseases, virus infections and rare diseases. The first product candidate is a novel AAT formulation for inhalation to treat emerging inflammatory diseases of the lung and respiratory virus infections.

60 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology

Immunotherapy against senescence StarkAge Therapeutics is a privately-held biotechnology start-up, whose ambition is to delay or halt disease progression and improve quality of life of patients with age-related diseases, associated with senescent cells accumulation. It builds on its unique disease-specific exosomal / EV technology while harnessing immunotherapy approach, to address very large senescence unmet medical needs.

69 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Complete genes for complete cures Kano Therapeutics is a biotech startup enabling safe, effective, and flexible correction of gene-length stretches of DNA through a new class of biomaterials: circular single-stranded DNA. By building a “one stop shop” product development platform for single-stranded DNA templates that combines manufacturing, application, and computational tools we bridge the gap between editing genes and totally replacing them. Biotechnology, DNA therapeutics, Gene therapy, CRISPR, and Biological engineering

113 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

‘Off-the-Shelf’ Curative Cell Therapies About Us: Cell BioEngines, Inc., founded in Dec 2022, is a clinical-stage biotech company focused on developing allogeneic 'off-the-shelf' stem cell and its derived therapies as ‘drugs’ for human disease treatment. The company utilizes a ‘plug-and-play’ proprietary platform technology that transforms universal ‘non-gene-modified’ donor blood stem cells from umbilical cord, to produce high-quality, pure and potent, multiple clinical grade cells at scale. This innovative method aims to make stem cells and its derived therapies more accessible and efficient. Its lead product is currently in Phase 1 trials for the treatment of hematopoetiic neoplasms not curable with …

75 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

GRObio’s groundbreaking science expands the amino acid alphabet to deliver on the promise of protein-based therapies. GRO Biosciences transforms protein therapeutics with new amino acid building blocks to treat incurable diseases. Protein therapeutics, Biologics, and Genomic recoding

99 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Therapeutics for the Disease of Aging Immune therapy platform targeting Dark Genome antigens that contribute to aging, cancer, diabetes, and neurodegenerative diseases Oncology, Aging, Dark Genome, ALS, Diabetes, and Longevity

198 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Since more than 10 years, AnyGenes® scientists develop and produce innovative high throughput screening products for signaling pathway analysis. These kits and reagents allow high throughput transcriptomic analysis of a large collection of signaling pathways in many species, biomarkers identification and validation, as well as validation of microarrays results. AnyGenes®, with its innovative & cost effective technologies, products and its proprietary molecular platform, helps scientists to accelerate their projects, publications, and biotech companies for drug development and biomarkers validation. Located in Paris, within Tenon Hospital in the 20th arrondissement, AnyGenes® constitutes a key player in the Biotechnology field. Supported by …

21 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Playing music to cells Kolibri revolutionises the way we grow and engineer cells at scale using acoustic waves. 🔍 Book a discovery call: https://calendly.com/tamsin_kolibrilab/discovery-call Showing 10x increase in cell density and 50x reduction in production costs, our patented bioreactors help our partners in drug development unlock patient access to gene therapies, with a proof of principle in AAV gene therapy. Being cell-agnostic and scalable, our process has significant potential across a range of high-value cell-based therapies - or in the cellular agriculture space more broadly. gene therapy, biomanufacturing, cellculture, acoustics, hardtech, and biotech

137 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Vivet Therapeutics is dedicated to developing innovative gene therapy treatments for orphan diseases. Vivet Therapeutics is focused on optimizing gene therapy through collaborating with the Fundacion para la Investigacion Medica Aplicada (CIMA, Universidad de Navarra) to develop new AAV vectors specifically targeting the liver and generating new technologies to optimize gene delivery and long term expression. Gene Therapy

91 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Transforming cancer and autoimmune treatments with unique IL-1RAP targeting approaches Advesya is a pioneering and transformative biotechnology company developing therapies for difficult-to-treat cancers. Haematology & Oncology, Antibody Drug Conjugate, Cell Therapy, and Autoimmune

398 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Dedicated to developing treatments for rare diseases originated from nonsense mutations Genvade aims to harness the power of nonsense mutation readthrough molecules to develop treatments for some of the most burdensome rare diseases. Our lead compound targets indications include cystic fibrosis, Duchenne muscular dystrophy and other genetic diseases. small molecules, drug discovery and development, rare diseases, nonsense mutation corrector, cystic fibrosis, genetic diseases, oncology, readthrough, and Duchenne

101 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Neocor is dedicated to pioneering transformative therapies in cardiac care We are currently developing a novel gene therapy approach targeting ischemic and rare genetic cardiac diseases, and moving from lab preclinical trials to regulatory trials. The Company was founded in October and has received strong traction since inception. We will be looking to strengthen our human and financial ressources in the coming month in order to start the regulatory pre clinical trials. gene therapy, biotechnology, rare disease, and cardiology

118 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We build high tech equipment supporting end-to-end development and manufacture of cell and gene therapies. We build high tech equipment supporting end-to-end development and manufacture of cell and gene therapies. biotech, medtech, cell therapy, gene therapy, CAR-T, MSC, iPS, ATMP, Tissue Engineering, cell based therapies, biotherapies, RMAT, and Manufacturing

428 similar entities Tags: FrenchTech2030 Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Integra Therapeutics is a biotech company engineering the next generation of gene writing tools to cure genetic diseases At Integra Therapeutics we have combined the precision of CRISPR systems with the gene transfer efficiency of viral integrases and transposases. Harnessing what nature has evolved to introduce large pieces of DNA into the genome, together with the precision of sequence specific DNA binding proteins, has allowed for unprecedented efficiency in programmable gene delivery.

112 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies. Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology. Our research and development programs target indications with substantial unmet medical needs: NASH, MPS and oncology. Drug Discovery, Biotech, Oncology, Fibrosis, Lysosomal Storage Disorders, NASH, and SSc

154 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

RNA Therapeutics We develop first-in-class RNA-based therapies, with lead programs in Head & Neck Squamous Cell Carcinoma (HNSCC) and Facioscalpulohumeral Muscular Dystrophy (FSHD). Our approach to drug design revolves around using genomic patient data to create highly tailored therapeutics – the right drug for the right patient. Our proprietary DREAmiRTM platform utilizes genomic and outcome data from thousands of patients to identify underlying genetic changes that cause their disease, and then creates a novel RNA therapeutic that can directly target and fix that genetic abnormality.

113 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology Data Analytics

Platelet-derived Regenerative Therapy for CNS Disorders InVenis Biotherapies is a biotech compagny, spin-off from academic laboratory U1172 and Taipei Medical University, developping innovative regenerative therapies based on blood platelet. Thanks to the high therapeutic potential of our product, we target the most severe diseases involving cell death, as the amyotrophic lateral sclerosis.

217 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Targeted imaging and therapies Zionexa is an international and innovative company developing and commercializing molecular imaging solutions, in-vivo biomarkers for targeted therapies in oncology, to improve patients’ pathway and bring them a better quality of life. Molecular Imaging, Oncology, Targeted therapies, CDx, Radiopharmaceuticals, and Biomarkers

62 similar entities Type: Startup Activities: biotech deeptech

The CNS Regeneration Company Axoltis pharma is a biopharmaceutical company dedicated to develop a first-in-class disease-modifying drug to treat patients with neurodegenerative or traumatic neurological disorders with high unmet medical needs. Our innovative approach: combining Preventative, Neuroprotective, Regenerative & Remodeling properties in a single drug, as the key to cure complex neurological disorders. Our products are first-in-class multifunctional peptides with high potential in many CNS disorders. neurodegenerative diseases, neurodegeneration, spinal cord injury, peptide, neuroprotection, neural repair, regeneration, drug, biotechnology, pharma, CNS, neurology, ALS, Parkinson, and Multiple Sclerosis

62 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

DNA Synthesis Uncompromised Molecular Assemblies, Inc. is a private life sciences company developing an enzymatic DNA synthesis technology designed to power the next generation of DNA-based products. The company’s patented Fully Enzymatic Synthesis (or FESTM), based on making DNA the way nature makes DNA, produces long, high quality, sequence-specific DNA reliably, affordably, and sustainably. FES technology will enable the reading and writing of DNA for many industries, including industrial synthetic biology and precision medicine, as well as emerging applications of nanomachines and bio-based electronics. Molecular Assemblies is headquartered in San Diego. *Fully Enzymatic Synthesis and FES are the trademarks of …

66 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Neurotech & photomedicine REGEnLIFE is an innovative company developing cutting-edge therapy for neurodegenerative disorders. Our company supports a non-invasive medical approach based on physical sciences. Our mission is to develop innovative and responsible technologies to face up to medical challenges and public health needs. Our goal is to provide to healthcare professionals a technology able to alter the progression of neurodegenerative diseases, in order to improve the health and quality of life to promote a healthy aging process. Our technology consists in a novel medical device dedicated to people living with neurodegenerative diseases, specifically Alzheimer-type dementia. MedTech, NeuroTech, Neurophonic, Photonics, …

87 similar entities Type: Startup Activities: biotech deeptech healthtech manufacturing Technologies: Synthetic Biology

Targeting protein interactions for health Founded in 2023, TheraPPI Bioscience is a biotechnology company whose science originates from the CRCL (Centre de Recherche de Cancérologie de Lyon, France). We modify protein interactions to offer treatments where current therapies fail. Our approach represents a paradigm shift in tackling cancer resistance and non-curable rare diseases protein-protein interaction, PPI, small molecule, therapeutics, oncology, and rare disease

80 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

At Corlieve, we are focused on bringing novel therapeutic options to patients with severe neurological disorders. Corlieve Therapeutics, a fully owned subsidiary of UniQure, is a biotechnology company focused on bringing novel therapeutic options to patients with severe neurological disorders.

60 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Innovative therapies for peripheral nerve diseases Nervosave Therapeutics discovers and develops therapies that slow, stop and reverse a broad range of demyelinating peripheral nerve diseases. Our first aim is to develop best in class Gene Therapy for CMT1A patients and beyond for all demyelinating CMT diseases. We develop robust discovery programs targeting both CMT diseases and acquired demyelinating peripheral neuropathies such as diabetic peripheral neuropathy and Guillain-Barré syndrome.

9 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Coave therapeutics Coave Therapeutics is a clinical stage biotechnology company focused on developing life changing gene therapies in rare Ocular and CNS (Central Nervous System) diseases. We are pushing the boundaries of gene therapy through application of our AAV-Ligand Conjugates platform (ALIGATER) that enables targeted delivery, enhanced gene transduction and tissue distribution to improve the effectiveness of advanced gene therapies for rare diseases. Our strategy is to advance a pipeline of novel therapies targeting rare ocular and CNS diseases where targeted gene therapy has the potential to be most effective, where there is a clear unmet need and where success …

86 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology

Delivering the next generation gene therapies AAVantgarde is a clinical-stage, international biotechnology company (headquartered in Italy) that has developed two proprietary adeno-associated viral (AAV) vector platforms to address the DNA cargo capacity limitations of AAV vectors Gene Therapy, Ophthalmology, and Rare diseases

338 similar entities Type: Startup Activities: healthtech biotech deeptech Technologies: Synthetic Biology

Combining human and machine intelligence to discover the next generation of therapeutic antibodies. LabGenius Therapeutics ("LabGenius") is a drug discovery company pioneering the discovery of next-generation therapeutic antibodies. The company’s discovery platform, EVATM, integrates several cutting-edge technologies drawn from the fields of artificial intelligence, robotic automation and synthetic biology. While EVATM is both modality and format-agnostic, LabGenius' internal pipeline is focussed on the development of selectivity-enhanced antibodies for the treatment of solid tumours. The company's novel approach is delivering a pipeline of antibody therapeutics with best-in-class killing profiles. Medical, Health, and DNA Libraries

62 similar entities Type: Startup Activities: healthtech biotech deeptech Technologies: A.I. Robotics Synthetic Biology A.I. - Machine Learning

Guiding clinicians towards personalized treatment and enhancing quality of life for patients Using molecular structures to choose the best therapy. Currently focusing on mutations in EGFR and other lung cancer drivers. Working closely with the Molecular Tumor Board at the UMCG #umcg and patient organizations across Europe.

65 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

CDMO expert specialized in gene delivery Flash BioSolutions is a World-class CDMO expert in lentiviral vector manufacturing : With our continuum from research to the clinic we support you throughout your projects from R&D to GMP grade. We provide purified and highly concentrated particles from small scale to large scale with the same vector specifications. Flash BioSolutions provides integrative lentiviral vectors and RNA particles. Lentiviral vectors - LentiCare® : Conventional lentiviral vectors, which lead to DNA integrated into the genome, are a leading delivery method for applications which require a stable and long-term gene expression. Ideal for Gene Therapy and …

15 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

AbLeads is a young biotech startup developing innovative solutions in Oncology, through the generation of novel, personalized therapeutic antibodies. Learn More on https://ableads.fr Biotechnology, Oncology, Immunotherapy, Therapeutic Antibodies, and Personalized Medicine

574 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Pinpoint Gene Therapy At EG427 our unique, non-replicative Herpes Simplex Virus type 1 (HSV-1) based vector platform called HERMES, delivers, with pinpoint precision, highly selective, durable expression of disease modifying transgenes to address prevalent diseases in neurology. Our lead asset EG110A, for the treatment of neurogenic bladder dysfunction, has received IND clearance in June 2024 from the US FDA. Our revolutionary approach to the treatment of this disease aims at providing patients with a comprehensive, long-term solution to their bladder management, through a highly selective molecular biology approach overcoming the drawbacks of current standard of care. Our HQ and labs …

16 similar entities Type: Startup Activities: biotech healthtech deeptech Technologies: Synthetic Biology

Developing novel therapies for rare bone diseases Innoskel is a pioneering platform biotechnology company developing therapies for rare bone diseases. Innoskel's first asset is a treatment option for a group of rare skeletal disorders collectively known as type 2 collagenopathies, the most severe of which with symptoms present from birth is Spondyloepiphyseal Dysplasia congenita (SEDc), the second leading cause of dwarfism worldwide. Innoskel’s lead gene therapy asset for SEDc has demonstrated good efficacy in proof-of-concept studies. The company’s fundamental mission is to improve the lives of patients living with rare bone disorders and to answer their unmet needs, keeping their …

19 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Our mission: find solutions for hearing disorders Sensorion is a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a planned Phase 2 proof of concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) and, with partner Cochlear Limited, a study of SENS-401 in patients scheduled for cochlear implantation. Sensorion has entered into a broad strategic collaboration with the Institut Pasteur focused on the genetics of hearing. It has two gene therapy programs …

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Seamless Therapeutics is overcoming the boundaries of gene editing by unlocking the full potential of recombinases. Seamless Therapeutics is changing the paradigm of gene editing through a pioneering approach to restore health in patients with severe conditions in a safe and precise manner. Our technology platform unlocks the reprogramming of recombinases, a highly versatile class of enzymes. We are applying our proprietary know-how to develop a pipeline of disease-modifying product candidates across a broad spectrum of indications to expand the therapeutic potential of gene editing.

44 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

Plant-based Nanotechnologies for autoimmune diseases diagnoses and therapy DIAMANTE (Nano-Technologies for Autoimmune Disease) is a biotech company focused on the use of plants for producing high value-added molecules. The company was funded in 2016 with the development of new tools in autoimmune disease diagnosis and now we are growing approaching therapeutics applications. As an innovation-oriented female company, our value proposition is the creation of novel therapeutic approach for autoimmune diseases based on the restoration of self-tolerance, using plant viruses displaying immunodominant peptides. Diamante, thanks to the Regione Veneto and particularly though the national grant POR FESR AZIONE 1.1.1 2020/2021, has …

55 similar entities Type: Startup Activities: nanotech biotech deeptech healthtech Technologies: Synthetic Biology

Precision treatment of immune disorders Polyneuron is a growing Basel-based biotechnology company active in the area of autoimmune disease treatments. The company was founded in 2014 as a spinout company from the University of Basel to develop novel treatments to combat immune disorders using its Antibody-CatchTM technology platform. The company currently employs about 10 people and has raised a significant amount in equity funding from top-tier VCs. We are a team of passionate and experienced scientists, entrepreneurs and investors willing to bring new therapies to patients.

129 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Life-Transforming Medicines for Patients Living with Serious Rare Diseases VectivBio AG is a clinical-stage biotechnology company focused on rare diseases with a well-defined biology that can be targeted with transformational therapeutics. VectivBio was formed in 2019 as a spinout from Therachon, a biotechnology company acquired by Pfizer, Inc., for its program in achondroplasia, with the ambition to continue to have an impact on people’s lives by bringing transformational medicines to patients with serious rare conditions. The company is led by a world-class leadership team with deep expertise in rare diseases and a track record of success in R&D, commercialization and …

104 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Our vision: To profoundly impact the lives of patients with orphan diseases and their families Orphazyme is a global biopharmaceutical company, headquartered in Denmark, with a rapidly growing presence in the United States. We are pioneering a new kind of treatment, applying our specialized expertise to bring innovative therapies to patients with neurodegenerative orphan diseases. With a late-stage drug pipeline, we are relentless in our commitment to advancing treatments and making a profound impact for those touched by these rare, serious diseases. Today we are listed on Nasdaq Copenhagen (TICKER: ORPHA.CO) and Nasdaq U.S. (TICKER: ORPH), and are expanding our …

26 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

AveXis is now Novartis Gene Therapies Novartis Gene Therapies (formerly AveXis) is reimagining medicine to transform the lives of people living with rare genetic diseases. Utilizing cutting-edge technology, we are working to turn promising gene therapies into proven treatments, beginning with our transformative gene therapy for spinal muscular atrophy (SMA). Follow us on LinkedIn: https://www.linkedin.com/company/novartis-gene-therapies/ How to reach us: Novartis Gene Therapies 2275 Half Day Road, Suite 200 Bannockburn, IL 60015 Email: gtx.communications@novartis.com Office Phone: 847.572.8280 Toll-free Phone: 844.428.3947 Gene Therapy, Synthetic Biology, and Spinal Muscular Atrophy

68 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Pursuing curative gene therapies to give patients and their families more bluebird days. bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days. With a dedicated focus on severe genetic diseases, bluebird has industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. We custom design each of our therapies to address the underlying cause of disease and have developed in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy …

Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Pioneering DARPin Therapeutics for Patients Molecular Partners AG is a clinical-stage biotech company pioneering the design and development of DARPin therapeutics, a new class of custom-built drugs for medical challenges other modalities cannot readily address. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. Molecular Partners leverages the advantages of DARPins to provide unique solutions to patients through its proprietary programs as well as through partnerships with leading pharmaceutical companies. Molecular Partners was founded in 2004 and has offices in both Zürich, Switzerland and Concord, MA, USA. DARPins, Oncology, Immuno-Oncology, Radiopharmaceuticals, …

82 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Driving gene therapy breakthroughs to develop transformative AAV treatments for patients with ciliopathies like BBS Axovia Therapeutics is dedicated to the research and development of novel AAV gene therapies that target key aspects of ciliopathies, addressing the devastating impact of the disease head-on for patients, their families and caregivers. Axovia is currently developing therapies for patients with mutations in the BBS1 gene which manifests as Bardet Biedl Syndrome. Our initial goal is to halt the progression of BBS by targeting the most debilitating aspects of the neurological, metabolic and retinal dysfunctions.

Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

A revolution in gene therapy for neurodegenerative disorders. At AviadoBio, we are relentlessly chasing cures by translating groundbreaking science and precision delivery into life-changing medicines for people living with frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). With our deep understanding of the brain and our suite of proprietary gene therapy platforms and delivery technologies, we are working relentlessly to overcome the challenges of delivering the right drug to the right place. Our innovative, neuroanatomy-led approach is designed to maximize the therapeutic potential of gene therapy to halt or potentially reverse neurodegenerative diseases. The Company’s technology is based on pioneering …

50 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering Macrophage Cell Therapy for Transformative Outcomes in Inflammatory Organ Diseases Resolution Therapeutics is a biotechnology company developing macrophage cell therapy to treat inflammatory organ disease. The company was founded following a productive collaboration between Edinburgh’s Centre for Regenerative Medicine, the Scottish National Blood Transfusion Service, and Syncona Investment Management Limited. The company is based in the Centre for Regenerative Medicine on the Edinburgh Royal Infirmary Campus, and is backed by Syncona. Our initial focus is in chronic liver disease. It is the only chronic disease still on the rise in western countries, and affects millions of people worldwide. Unfortunately, …

29 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Changing the paradigm in Friedreich's ataxia Biointaxis is an academic spin-off focused on the development of gene therapies for neurodegenerative disorders. Biointaxis lead product is a gene therapy product for Friedreich ataxia.

59 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

We are Purespring. We are on a mission to radically transform the treatment of kidney diseases. Purespring, which launched in November 2020 with £45 million of funding from Syncona Ltd, is the first company to be directly targeting the podocyte, a specialized kidney cell implicated in many kidney diseases, through AAV gene therapy. This approach is based on the work of Professor Moin Saleem, Professor of Paediatric Renal Medicine at the University of Bristol, where he heads a world leading group researching glomerular diseases. biotechnology, gene therapy, and kidney diseases

36 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering proteasome therapeutics for a new approach to complex disease Booster Therapeutics is pioneering a new class of medicines that activate proteasomes (the cell’s natural quality control machinery) to treat a range of complex indications. The company is developing a multi-disease pipeline, with an initial focus on neurodegenerative diseases associated with impaired proteasome function.

68 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Reconcile the time of Research with the one of Medecine APTEΞUS was created to provide clinicians and their patients suffering from orphan diseases, an innovative service of clinical biology that perfectly meets the emerging challenge of individualized medicine. APTEΞUS is engaged in patient-centric discovery of individualized treatments. Our technology allows the testing of thousands of molecules directly on primary cells sampled from patient with inborn error of metabolism. We can rapidly identify molecules that specifically correct the very molecular defect of the patient and give him a new opportunity to be cured.

35 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Catalyzing the development of transformative genetic-based therapeutics from concept to clinic. Dedicated to discovery + translational research and led by Dr. James Wilson, the Gene Therapy Program (GTP) at the University of Pennsylvania focuses on the development of next-generation gene transfer vectors and their application in the treatment of a variety of acquired and inherited diseases. Dr. Wilson's commitment to patients with rare diseases stems from his days as a graduate student and medical student at the University of Michigan between 1977 and 1984. He was discouraged by the lack of available treatments for rare disease patients, but optimistic that …

12 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Reach New Heights With Your Biomarkers At OakLabs Scientific, we believe that each of us can live longer healthy. In a society where individual healthcare is increasingly challenging, we are pioneering ways to detect and avert disease before it occurs. Using our unique Artificial Intelligence algorithms and high-molecular-weight data, we are exploring individual health status in unprecedented depth. gene expression analysis, biotechnology, research, biomarkers, biomarker signatures, and companion diagnostics

84 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

VectorBuilder is a global leader in gene delivery technologies. As a trusted partner for thousands of labs and biotech/pharma companies across the globe, VectorBuilder offers a full spectrum of gene delivery solutions covering virtually all research and clinical needs from bench to bedside. VectorBuilder is the future of gene delivery. Our mission is to provide end-to-end solutions for all gene delivery needs spanning both research and therapy. We strive to offer innovative and high-quality products and services while maintaining rapid turnaround and exceptional affordability. Our “white-glove” customer care is supported by a PhD-level team with decades of collective experience to …

12 similar entities Type: Startup Activities: deeptech manufacturing Technologies: Synthetic Biology

High-Capacity Gene Therapy Vector Platform to Address Prevalent Diseases GQ Bio is pioneering a high-capacity gene therapy vector platform (HCAd) that addresses some of the big challenges in the gene therapy field: Transfer of large and multiple genes with a single vector, highly efficient gene delivery (high transduction efficiency), and large-scale manufacturability. Based on its HCAd vector platform, GQ Bio develops transformative treatments for chronic, prevalent conditions such as osteoarthritis and intervertebral disc degeneration. GQ Bio is headquartered in Hamburg, Germany and has sites at Luckenwalde (greater Berlin area), Germany and Liège, Belgium. biotechnology, gene therapy, osteoarthritis, drug development, human …

64 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Building on innovative science to create treatments for patients in need ResoTher Pharma ApS is a biotechnology company focused on developing novel and effective peptide therapeutics for cardiovascular disease by targeting inflammation. Biotechnology, Drug Development, and Pharmaceutical Industry

662 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

AstronauTx is tackling dementia through improving brain physiology AstronauTx is at the forefront of a novel approach to treating neurodegenerative diseases. We have a unique portfolio of small-molecule therapeutics to restore dysregulated physiology to both improve symptoms and modify disease.

101 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Seed Therapeutics is pioneering the science of improving human health by creating “molecular glues”: novel therapeutics that degrade disease-causing proteins that have heretofore remained “undruggable.” Through ongoing collaborations with world-leading academic experts in the field, and in partnership with seasoned drug development and commercialization experts, Seed Therapeutics is establishing a growing pipeline of exciting drug candidates on a path to clinical and commercial success. Our mission is to positively impact human health by creating novel protein degradation therapeutics for the treatment of severe diseases for which health care professionals currently have limited options to offer to patients. Biotechnology, Biotherapeutics, Cell …

96 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

We're committed to translating our ground-breaking science into genomic medicines that transform patients’ lives. For Sangamo Therapeutics, science is a means to develop new medicines with the potential to transform the lives of patients living with serious genetic diseases. Our scientists are leaders in the discovery, research and development of technologies enabling gene-based therapeutic development. Currently we are conducting clinical trials, including the first ever in vivo human genome editing studies. To learn more about Sangamo, visit the our website at www.sangamo.com. Biotechnology, Genome Editing, Gene Therapy, MPS II, MPS I, Hemophilia A, Hemophilia B, Beta Thalassemia, Gene Therapy, Fabry, …

40 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering a new era in precision medicine for women's health A clinical-stage biotechnology company pioneering a female-focused precision medicine approach using validated biobanks for the discovery, development, and commercialization of novel therapeutics and companion diagnostics in women's health. ovarian cancer, endometrial cancer, fibrosis, endometriosis, post surgical adhesions, surgery, women's health, fitness, health, lifestyle, precision medicine, Artificial Intelligence, Machine Learning, Biobank, gynecology, reproductive medicine, infertility, cervical cancer, pcos, femtech, life sciences, and healthcare

245 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology A.I.

Enabling our healthcare client partners to accelerate breakthrough cancer solutions. Sus Clinicals solves major problems in qualifying new cancer drugs, devices, diagnostics and therapies. Using a proprietary model of testing on genetically-modified pigs pioneered at the University of Illinois, Sus Clinicals leverages the inherent advantages of a patent-pending large animal testing methodology combined with novel clinical approaches to reduce false positives, model the interactions of multiple diseases, and accelerate progress toward human trials for the most promising therapies.

30 similar entities Type: Startup Activities: pettech deeptech biotech Technologies: Synthetic Biology

What If You Could Repair Broken Genes? What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We’re a clinical stage genome editing company focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Our goal is to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. We are a vibrant company full of hope, possibilities, and a belief that, working together as One …

28 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Clinical-stage biopharmaceutical company developing transformative therapies to treat devastating human diseases Caribou Biosciences is a leading clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. Our next-generation genome-editing technology enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. We believe the future of cell therapy is off-the-shelf, and we are advancing our pipeline of off-the-shelf, or allogeneic, cell therapies from our CAR-T cell therapy platform as readily available treatments for patients with hematologic malignancies and autoimmune diseases. Next-generation CRISPR genome editing, allogeneic CAR-T cell therapies, oncology, and …

85 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Ahead of the Curve Orna Therapeutics is a biotechnology company reshaping RNA therapeutics. We are developing the leading circular RNA technology platform (oRNA®) and unprecedented lipid nanoparticle (LNP) delivery solutions – unlocking the therapeutic possibilities of circular RNA and pioneering the next chapter of safe and effective in vivo therapies for the treatment of disease. Website: www.ornatx.com

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

OncoDNA is a genomic and theranostic company specializing in precision medicine for the treatment of cancer and genetic diseases. The company helps clinicians, academic researchers and biopharma companies to outsmart molecular complexity with the mission of delivering the promise of precision medicine. The company not only provides clinical guidance for the treatment and real-time monitoring of late-stage cancer patients but also supports research and drug development in cancer and genetic diseases. Since its early days in 2012, OncoDNA has grown into a corporate group of companies with world-renowned expertise. The Group offers a unique portfolio that combines NGS services, biomarker …

69 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Unlocking access to genes with unparalleled accuracy Our mission is to enable synthetic biologists, by using our technology to unlock access to genes with unparalleled accuracy. We produce genes for a range of biotechnology customers including those in the pharmaceutical, agriculture and diagnostics sectors. Our technology offers access to long and complex gene sequences, which are normally difficult to produce. We are based in Cambridge UK, but we serve companies across the world. Camena's technology is positioned to enable researchers and the synthetic biology revolution. Twitter: @camenabio DNA synthesis, Complex genes, Synthetic Biology, synbio, and Gene synthesis

110 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Pioneering RNA cell therapy for autoimmune disease Cartesian Therapeutics is a clinical-stage company pioneering mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a potential first-in-class mRNA CAR-T in Phase 2b clinical development for patients with generalized myasthenia gravis and Phase 2 development for systematic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA mRNA CAR-T. For more information, please visit www.cartesiantherapeutics.com Immunotherapy, Oncology, Molecular Biology, Immunology, Myasthenia Gravis, ARDS, Cell Therapy, NETs, Gene Therapy, Cancer Research, multiple myeloma, …

62 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Embleema is the regulatory-grade health data platform to accelerate new drug discovery and release new treatments sooner Embleema's software platform brings precision medicine sooner to patients by collecting and generating regulatory-grade evidence. Our platform natively unifies clinical, molecular and real-world data and is the sole one used by the FDA for its regulatory evaluation of health products involving genomic datasets. The protocols and algorithms contained in our platform are also the basis for future CDISC standards for cell and gene therapies. The FDA also uses our platform to produce regulatory grade genomic sequences for SARS-CoV-2 and other microbial pathogens (project …

29 similar entities Type: Startup Activities: healthtech biotech deeptech Technologies: Blockchain/Cryptocurrency

Genenta is a clinical stage immuno-oncology company Genenta (Nasdaq: GNTA) is a clinical stage immuno-oncology company developing a proprietary hematopoietic stem cells therapy for the treatment of a variety of solid tumor cancers. Genenta's first in class product candidate is TemferonTM, which is designed to allow the expression of immune-therapeutic payloads within the tumor microenvironment by bone marrow derived myeloid cells and enable a durable and targeted response. Genenta has completed a Phase 1 trial for newly diagnosed Glioblastoma Multiforme patients with an unmethylated MGMT gene promoter, which suggests the potential reprogramming of the tumor microenvironment and inhibiting of myeloid …

10 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Empowering Therapies with Precision Data BIOMAKERS is a global Precision Medicine Company that produces complex & advanced genomic data + RWE to make cancer patients live longer and transform oncology data-driven Drug Development globally. having built an unprecedented platform that enables Diagnosis, Treatment, Drug Development, Target discovery and AI for Cancer and Rare Diseases, having developed genomic products in the 4 Stages of the Biopharmaceutical chain and providing the largest LATAM genomic representation in the global Oncology Drug Development Landscape. BIOMAKERS provides extensive genomic and molecular Testing services for cancer & rare disease patients in +17 countries in Latin America. …

70 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I.

Bringing Hope and Answers to Those Navigating Rare Conditions Our mission is to bridge critical gaps in access, ensuring that individuals and families affected by rare conditions receive the expert guidance they need. Through timely genetic counseling, streamlined test ordering and clinical trial matching, we accelerate diagnoses and connect patients with potential life-changing treatments. Genomics, Genetics, Precision Medicine, Medical Practice, Genetic Counseling, DNA, Genome, Sponsored Testing, Clinical Trials, Health Systems, Laboratories, and rare disease

5 similar entities Type: Startup Activities: healthtech

We bring life-saving genomics to hospitals, physicians and patients everywhere. Quantgene decentralizes genomics to bring precision medicine to everyone. Our turnkey genomics platform empowers hospitals to move life-saving genomic diagnostics inside their organizations, unlock powerful new sources of revenue and become a driving force in clinical discovery. From complete genomic profiling to hereditary cancer testing and multi-cancer early detection, we help hospitals, physicians and patients to unlock the full power of precision genomics. Cancer diagnostics, biotechnology, genomics, machine learning, oncology, precision medicine, cancer screening, deep sequencing, cancer, innovation, AI, and Cancer Detection

89 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: A.I. A.I. - Machine Learning Synthetic Biology

Giving Life to Science PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including two that have received both U.S. FDA clearance and European marketing authorization and a third (KarXT) that has been filed …

64 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Unlocking New Targets to Transform the Treatment of Neurodegenerative Diseases Unlocking New Targets to Transform the Treatment of Neurodegenerative Diseases neurodegeneration, RNA therapeutics, physiological upregulation, post-transcriptional upregulation, mRNA, ASO, and SINEUP

279 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Accelerating treatments for millions of patients Arctic Therapeutics is a clinical-stage biopharmaceutical company on a mission to treat and even prevent some of the world’s most pressing diseases by utilizing genetic sequencing to analyze and map the genetic causes of diseases at a granular level, applying our findings to develop effective treatments. Our company was founded by Dr. Hakon Hakonarson in 2015 as a spin-off from the US-based Center for Applied Genomics (CAG), which he launched in 2006 and established it as the largest pediatric biobank and genomic database in the world. We maintain close research relationships with CAG and …

165 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Dedicated to develop the medicines of the future ViGeneron was founded in 2017 as a spin-off of the Ludwig-Maximilians-University (LMU) Munich. At ViGeneron we are dedicated to develop innovative gene therapies based on our two unique and proprietary technology platforms. ViGeneron will leverage its two technology platforms to address unmet medical needs with in-house gene therapy programs for selected retinal disorders. Together with partners we will exploit our ViGeneron technologies for additional indications. Gene Therapy, Inherited Retinal Disorders, and AAV vector

52 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Improving the safety and efficacy of gene therapies using AI Concinnity is developing an AI-driven RNA design platform to build gene control systems for gene and cell therapies. Our RNA-based control systems will form part of the gene therapy cassette and enable precise control of therapeutic activity. Such control systems have huge potential to enhance both patient safety and therapeutic efficacy, for example by allowing a gene therapy to dynamically adjust its activity in response to patient disease state, recognise tissue type, or by allowing clinical control of the therapy after administration. Gene Control, RNA, Artificial Intelligence, Synthetic Biology, and …

46 similar entities Type: Startup Activities: deeptech Technologies: A.I. Synthetic Biology

We turn blood stem cells into living drug factories At Immitra Bio, we are pioneering a next-generation gene therapy platform, harnessing Hematopoietic Stem Cells and their downstream cell lineages, such as red blood cells as living, in-vivo biotherapeutic protein factories. The CRISPR-Cas-based cell and gene therapy platform we are developing is versatile and promises to be easily reprogrammable.

221 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

At Maze, we envision a world where genetic insights inspire new medicines. Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows it to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. The company’s pipeline is led by two wholly owned lead …

17 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Revolutionizing in vivo gene delivery to usher in a new era of genetic medicines. Kelonia is pioneering a new wave of genetic medicines using its next generation gene delivery platform. The company’s simple and elegant cutting-edge in vivo gene delivery technology uses a few potent lentiviral vector-like particles to precisely and efficiently deliver in vivo genetic cargo to the desired target tissue, and only that tissue, every time. With an initial focus on developing transformational therapies for solid tumors and hematologic cancers, Kelonia is building a pipeline of genetic medicines for a wide range of diseases, with the bold goal …

18 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Unlocking the broad potential of RNA medicines to transform human health We are a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Our RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Our toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing us with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Our diversified pipeline includes clinical programs in Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington’s disease, …

67 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

Precision Engineered Medicines to Silence Diseases Our 20-plus years of RNAi experience together with our validated mRNAi GOLDTM platform make us a partner of choice for pharmaceutical companies looking to access the benefits of the siRNA and add this revolutionary modality to their discovery pipeline. As pioneers in the design and development of siRNAs (short interfering RNAs), Silence Therapeutics is advancing a new generation of medicines to potentially address the needs of patients who have limited or inadequate treatment options. Our mission is to use our technology to create a new generation of therapeutics which can improve outcomes for patients …

50 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

StemInsure®: Your Younger Cells For Life® Personalized Stem Cells, Inc. (PSC) is raising the standard of Stem Cell therapy. We are committed to providing high-quality stem cell processing services, as well as excellent technical, clinical, and regulatory support to physicians, clinical investigators, and patients.

61 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Engineering the future of RNAi-based medicines Founded by pioneering executives and scientists in RNAi, City Therapeutics is advancing next-generation engineering of small interfering RNAs (siRNAs) – the “trigger” molecules that mediate RNAi – to improve and expand the reach of RNAi-based medicines. City’s mission is to build the leading next-generation RNAi therapeutics company, unlocking RNAi’s transformative potential to help patients with a wide range of diseases.

87 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Leader in the development, production and sales of pharmacogenetics tests for cancer precision medicine. Diatech Pharmacogenetics, the leading Italian Precision Medicine company. Diatech Pharmacogenetics is a provider of molecular diagnostic tools for precision medicine. The company aims at simplifying complex molecular diagnostic procedures into easy end-to-end solutions, from nucleic acids extraction and their molecular analysis, to final reporting. The company has 10 years of experience in the successful implementation of several nucleic acid analysis technologies into regulated diagnostic pipelines; examples include pyrosequencing, mass spectrometry and digital molecular barcoding. Leading cancer centres in Italy and abroad rely on Diatech CE-IVD solutions …

34 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering therapies based on aptamer technology aptaTargets is a clinical stage biopharmaceutical company focused in developing therapeutic applications based on aptamer technology. Our candidates are neuroprotectants and immunomodulators being developed from preclinical stages up to clinical proof-of-concept. Biopharmaceutical, Biotechnology, Aptamers, Immunology, Stroke, and Inflammatory diseases

133 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

A new hope for patients affected by Alzheimer’s disease CaSRevolution is a research company specialized in devising innovative therapies for neurodegeneration diseases We have discovered a new mechanism that explains the progression of Alzheimer’s Disease and identified a potential therapeutic approach biotech, neurodegeneration, startup, and alzheimer

115 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Empowering patients to bridge rare disease research and trials through a revolutionary clinico-genomic databank. Backed by VCs and an IUK government grant, GeneHub is building the world's first patient-controlled, clinico-genomic databank to bridge rare disease research and clinical trials. GeneHub enhances patient visibility and engagement by elevating patients into verified, zero-party data partners equipped with longitudinal real-world data from primary and secondary care. To ensure privacy, patients must consent to researchers analysing their anonymised clinico-genomic data in secure, on-demand, clean rooms. Patients actively engaging with researchers benefit from free advanced diagnostics such as DNA and mRNA sequencing, accelerating clinical trial …

12 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We're on a mission to cure blindness with our transformational platform of advanced therapies Aurion Biotech is a clinical stage biotech company, developing a transformational platform of advanced therapies to cure blindness. Our first candidate is for the treatment of corneal endothelial disease, and one of the first clinically validated cell therapies for corneal care.

71 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing therapies for severe leukodystrophies Overview SynaptixBio is a rare disease biotech company that is pioneering ground-breaking treatments for severe leukodystrophies and other childhood neurodegenerative diseases. SynaptixBio’s mission is to deliver gene therapies for fatal leukodystrophies in children caused by loss of function or mutation in a single gene. Using a breadth of platforms including antisense oligonucleotide (ASO)-based technology, we can silence the expression of the toxic gene to reverse disease progression. This approach will create life saving treatments for severe genetic diseases that affect the central nervous system. Pharmaceutical, Biotech, Leukodystrophy, Rare Disease, H-ABC, Hypomyelination, Basal Ganglia, Cerebrllum, Neurology, …

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

On-target gene therapies Alia Therapeutics is a pioneering gene editing company with a vision to revolutionize medicine by curing genetic diseases at their roots. Alia’s versatile portfolio of novel CRISPR systems expands the range of targetable genomic sites and increases the precision of genetic modifications, bringing gene editing to the next level of specificity and safety, which are required for therapeutic applications.

69 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Swedish biotech company exploring reprogramming as the next leap forward in cancer immunotherapy Asgard Therapeutics is a private biotech company exploring the application of direct cell reprogramming technologies for cancer immunotherapies. Formed as a spin-off from Lund University, the Company is pioneering a gene therapy approach based on its proprietary TrojanDC technology, designed to set in motion immune responses based on the biological properties of professional antigen presenting cells. Backed by Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden, Asgard Therapeutics aims to build a pipeline of personalized cancer immunotherapies optimized to each unique patient. Cell Reprogramming, Cancer Immunotherapy, and …

147 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Revolutionizing drug delivery HHC medical is a health tech startup developing a platform technology for targeted and non-invasive drug delivery via wireless electroporation. Drug Delivery, Genetic therapies, and Enabling life-altering therapies

408 similar entities Type: Startup Activities: deeptech healthtech biotech Technologies: Synthetic Biology

Turning breaks into breakthroughs Broken String Bioscience’s technology platform, INDUCE-seq®, supports the development of cell and gene therapies that are safer by design.INDUCE-seq®, is an NGS-based DNA break mapping platform that enables companies developing cell and gene therapies to measure and quantify the specificity of off-target genetic edits and evaluate the associated genetic outcomes. The platform provides data-driven, actionable insights across the discovery, pre-clinical and clinical development stages to advance gene editing programs.

47 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology SaaS

Developing the Next Generation Gene Editing Technology Pencil Biosciences is developing a truly innovative gene modulation technology that can have an impact across a range of applications, including new therapeutic options for patients with rare diseases. Genome Engineering, Research and Development, and Gene Editing

299 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Changing the world, one sequence at a time. Synbio Technologies aims to become the most trusted provider of DNA solutions that empower scientific discoveries by providing highly-accurate and cost-effective synthetic biology services and products for researchers around the world. We have developed a full range of DNA reading (sequencing), DNA writing (synthesis), and DNA editing (engineering) capabilities for various applications, including diagnostic DNA probes, precision medicine, protein production, antibody discovery, vaccine development, novel enzymes, molecular breeding, biofuel implication, and more. Our scientific capabilities cover all facets of DNA synthesis and engineering, offering a full range of support for molecular biology …

76 similar entities Type: Startup Activities: manufacturing deeptech biotech Technologies: Synthetic Biology

A clinical-stage biotech pioneering a portfolio of disease-transforming therapeutics for CNS-mediated conditions Noema Pharma is a biotech company developing groundbreaking therapies to address the most disabling symptoms in orphan conditions of the brain and nervous system. Noema’s research and development is focused on understanding and meeting patient needs using our novel therapies. CNS

61 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Ascend is an advanced therapy development partner with a flexible platform featuring industry-leading analytics. Ascend is gene to GMP partner with deep expertise in advanced therapy development and commercialization. We offer unparalleled collaboration backed by expertise while working to develop your products from the bench through the clinic and beyond. Let’s build the future of advanced therapies together!

61 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Better Technology. Better Delivery. Developing a new generation of disease-modifying therapies. Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic neuromuscular and neurological disorders. Biotechnology, Chemistry, Biology, Bioscience, Life sciences, and Therapeutics

436 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Dedicated to Improving Life. Precision BioSciences, Inc. (Nasdaq: DTIL) is a clinical stage gene editing company developing in vivo gene editing with its highly precise and versatile ARCUS genome editing platform. ARCUS uses sequence-specific DNA-cutting enzymes, or nucleases designed for gene knock out, as well as highly complex edits for gene insertion and/or gene repair. Precision BioSciences is based in Durham, North Carolina. For more information about Precision BioSciences please visit www.precisionbiosciences.com. Gene Editing and Gene Therapy

59 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology